These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 22710919)

  • 21. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.
    Huang SY; Zhang YR; Guo Y; Du J; Ren P; Wu BS; Feng JF; ; Cheng W; Yu JT
    Alzheimers Dement; 2024 May; 20(5):3251-3269. PubMed ID: 38501315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice.
    Murphy MP; Beckett TL; Ding Q; Patel E; Markesbery WR; St Clair DK; LeVine H; Keller JN
    Neurobiol Dis; 2007 Sep; 27(3):301-11. PubMed ID: 17651976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.
    Tosun D; Schuff N; Mathis CA; Jagust W; Weiner MW;
    Brain; 2011 Apr; 134(Pt 4):1077-88. PubMed ID: 21429865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.
    Kung MP; Skovronsky DM; Hou C; Zhuang ZP; Gur TL; Zhang B; Trojanowski JQ; Lee VM; Kung HF
    J Mol Neurosci; 2003 Feb; 20(1):15-24. PubMed ID: 12663930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease.
    Tremblay C; Pilote M; Phivilay A; Emond V; Bennett DA; Calon F
    J Alzheimers Dis; 2007 Dec; 12(4):377-90. PubMed ID: 18198424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.
    Cohen AD; Price JC; Weissfeld LA; James J; Rosario BL; Bi W; Nebes RD; Saxton JA; Snitz BE; Aizenstein HA; Wolk DA; Dekosky ST; Mathis CA; Klunk WE
    J Neurosci; 2009 Nov; 29(47):14770-8. PubMed ID: 19940172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
    Waragai M; Okamura N; Furukawa K; Tashiro M; Furumoto S; Funaki Y; Kato M; Iwata R; Yanai K; Kudo Y; Arai H
    J Neurol Sci; 2009 Oct; 285(1-2):100-8. PubMed ID: 19552926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia.
    Petrou M; Bohnen NI; Müller ML; Koeppe RA; Albin RL; Frey KA
    Neurology; 2012 Sep; 79(11):1161-7. PubMed ID: 22933741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
    Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
    J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
    Technol Eval Cent Assess Program Exec Summ; 2013 Feb; 27(5):1-4. PubMed ID: 23589929
    [No Abstract]   [Full Text] [Related]  

  • 38. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
    Pike KE; Savage G; Villemagne VL; Ng S; Moss SA; Maruff P; Mathis CA; Klunk WE; Masters CL; Rowe CC
    Brain; 2007 Nov; 130(Pt 11):2837-44. PubMed ID: 17928318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET imaging of amyloid deposition in patients with mild cognitive impairment.
    Forsberg A; Engler H; Almkvist O; Blomquist G; Hagman G; Wall A; Ringheim A; Långström B; Nordberg A
    Neurobiol Aging; 2008 Oct; 29(10):1456-65. PubMed ID: 17499392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
    Klunk WE
    Arch Neurol; 2008 Oct; 65(10):1281-3. PubMed ID: 18852340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.